Tarsus Pharmaceuticals/$TARS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Ticker
$TARS
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
323
ISIN
US87650L1035
Website
TARS Metrics
BasicAdvanced
$1.7B
-
-$2.72
0.94
-
Price and volume
Market cap
$1.7B
Beta
0.94
52-week high
$57.28
52-week low
$20.08
Average daily volume
590K
Financial strength
Current ratio
5.57
Quick ratio
5.47
Long term debt to equity
21.02
Total debt to equity
21.132
Interest coverage (TTM)
-12.02%
Profitability
EBITDA (TTM)
-107.75
Gross margin (TTM)
69.14%
Net profit margin (TTM)
-44.91%
Operating margin (TTM)
-46.72%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
-16.05%
Return on equity (TTM)
-33.98%
Valuation
Price to revenue (TTM)
6.665
Price to book
4.95
Price to tangible book (TTM)
5.07
Price to free cash flow (TTM)
-21.371
Free cash flow yield (TTM)
-4.68%
Free cash flow per share (TTM)
-188.71%
Growth
Revenue change (TTM)
449.03%
Earnings per share change (TTM)
-42.18%
3-year revenue growth (CAGR)
113.14%
3-year earnings per share growth (CAGR)
8.11%
What the Analysts think about TARS
Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.
Bulls say / Bears say
Tarsus Pharmaceuticals secured a $200 million non-dilutive financing commitment from Pharmakon Advisors, enhancing its financial flexibility and supporting future growth initiatives. (globenewswire.com)
The company reported a 407.9% increase in revenue to $66.41 million for the quarter ended December 31, 2024, surpassing analyst expectations and indicating strong market demand for its products. (tradingview.com)
Analysts have raised their price targets for Tarsus Pharmaceuticals, with Oppenheimer increasing its target to $65.00 and maintaining an 'outperform' rating, reflecting confidence in the company's growth prospects. (mayfieldrecorder.com)
Insider selling activity, including the sale of 8,355 shares by Dianne Whitfield, may raise concerns about internal confidence in the company's future performance. (stocknews.com)
The company's stock experienced a 17.8% decline in the quarter ending December 31, 2024, which could indicate investor apprehension despite strong financial results. (tradingview.com)
While Tarsus Pharmaceuticals has received positive analyst ratings, the consensus target price of $54.20 suggests limited upside potential from current levels, which may temper investor enthusiasm. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TARS Financial Performance
Revenues and expenses
TARS Earnings Performance
Company profitability
TARS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tarsus Pharmaceuticals stock?
Tarsus Pharmaceuticals (TARS) has a market cap of $1.7B as of June 27, 2025.
What is the P/E ratio for Tarsus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of June 27, 2025.
Does Tarsus Pharmaceuticals stock pay dividends?
No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Tarsus Pharmaceuticals dividend payment date?
Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.
What is the beta indicator for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.